(0.07%) 5 476.90 points
(-0.02%) 38 771 points
(0.01%) 17 858 points
(0.27%) $80.55
(0.82%) $2.81
(0.10%) $2 331.40
(-0.33%) $29.30
(-0.11%) $969.80
(0.03%) $0.932
(-0.16%) $10.64
(0.06%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 24.21M |
Vidutinė apimtis | 5.97M |
Rinkos kapitalizacija | 0.00 |
EPS | $-0.390 ( Q3 | 2022-11-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0390 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0770 (94.83%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-11-01 | Gross Paul Edward | Buy | 4 625 | Common Stock |
2022-11-01 | Gross Paul Edward | Buy | 5 623 | Common Stock |
2022-11-02 | Gross Paul Edward | Sell | 2 135 | Common Stock |
2022-11-02 | Gross Paul Edward | Sell | 2 595 | Common Stock |
2022-11-01 | Gross Paul Edward | Sell | 4 625 | Restricted Stock Units |
INSIDER POWER |
---|
-5.87 |
Last 100 transactions |
Buy: 146 624 | Sell: 133 052 |
Tūris Koreliacija
Clovis Oncology, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
RXRAW | 0.853 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Clovis Oncology, Inc. Koreliacija - Valiuta/Žaliavos
Clovis Oncology, Inc. Finansinės ataskaitos
Annual | 2021 |
Pajamos: | $148.76M |
Bruto pelnas: | $109.93M (73.90 %) |
EPS: | $-2.18 |
FY | 2021 |
Pajamos: | $148.76M |
Bruto pelnas: | $109.93M (73.90 %) |
EPS: | $-2.18 |
FY | 2020 |
Pajamos: | $164.52M |
Bruto pelnas: | $123.22M (74.89 %) |
EPS: | $-4.38 |
FY | 2019 |
Pajamos: | $143.01M |
Bruto pelnas: | $108.32M (75.75 %) |
EPS: | $-7.43 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Clovis Oncology, Inc.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.